Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo

Neurotoxicology. 2014 Jan:40:23-32. doi: 10.1016/j.neuro.2013.10.004. Epub 2013 Nov 1.

Abstract

Recent studies on Alzheimer's disease (AD) have focused on soluble oligomeric forms of amyloid-beta (Aβ oligomer, AβO) that are directly associated with AD-related pathologies, such as cognitive decline, neurodegeneration, and neuroinflammation. Donepezil is a well-known anti-dementia agent that increases acetylcholine levels through inhibition of acetylcholinesterase. However, a growing body of experimental and clinical studies indicates that donepezil may also provide neuroprotective and disease-modifying effects in AD. Additionally, donepezil has recently been demonstrated to have anti-inflammatory effects against lipopolysaccharides and tau pathology. However, it remains unknown whether donepezil has anti-inflammatory effects against AβO in cultured microglial cells and the brain in animals. Further, the effects of donepezil against AβO-mediated neuronal death, astrogliosis, and memory impairment have also not yet been investigated. Thus, in the present study, we examined the anti-inflammatory effect of donepezil against AβO and its neuroinflammatory mechanisms. Donepezil significantly attenuated the release of inflammatory mediators (prostaglandin E2, interleukin-1 beta, tumor necrosis factor-α, and nitric oxide) from microglia. Donepezil also decreased AβO-induced up-regulation of inducible nitric oxide synthase and cyclooxygenase-2 protein and phosphorylation of p38 mitogen-activated protein kinase as well as translocation of nuclear factor-kappa B. We next showed that donepezil suppresses activated microglia-mediated toxicity in primary hippocampal cells using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. In intrahippocampal AβO-injected mice, donepezil significantly inhibited microgliosis and astrogliosis. Furthermore, behavioral tests revealed that donepezil (2 mg/kg/day, 5 days, p.o.) significantly ameliorated AβO-induced memory impairment. These results suggest that donepezil directly inhibits microglial activation induced by AβO through blocking MAPK and NF-κB signaling and, in part, contributing to the amelioration of neurodegeneration and memory impairment.

Keywords: Alzheimer's disaese; Amyloid-beta oligomer; Donepezil; Inflammation; Microglia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides / metabolism*
  • Amyloid beta-Peptides / toxicity
  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Cells, Cultured
  • Donepezil
  • Hippocampus / drug effects
  • Hippocampus / metabolism
  • Indans / pharmacology*
  • Inflammation Mediators / antagonists & inhibitors
  • Male
  • Memory Disorders / chemically induced
  • Memory Disorders / drug therapy
  • Mice
  • Mice, Inbred ICR
  • Microglia / drug effects*
  • Microglia / metabolism*
  • Piperidines / pharmacology*
  • Rats, Sprague-Dawley
  • Transcription Factor RelA / metabolism
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Amyloid beta-Peptides
  • Anti-Inflammatory Agents
  • Indans
  • Inflammation Mediators
  • Piperidines
  • Rela protein, mouse
  • Transcription Factor RelA
  • Donepezil
  • p38 Mitogen-Activated Protein Kinases